Table 2.
Short-term (28/90 days) survival rates for patients treated with lamivudine vs entecavir or patients with noncirrhotic HBV-ACLF vs cirrhotic HBV-ACLF.
| Nucleos(t)ide analogues | 28-day survival rate | 90-day survival rate | ||||
|---|---|---|---|---|---|---|
| SMT | ALSS | Overall | SMT | ALSS | Overall | |
| Lamivudine | 61.3% (95/155) | 64.1% (84/131) | 62.6% (179/286) | 41.9% (65/155) | 49.6% (65/131) | 45.5 (130/286) |
| Entecavir | 58.1% (90/155) | 77.1% (121/157) | 67.6% (211/312) | 45.8% (71/155) | 62.4% (98/157) | 54.2% (169/312) |
| p value | 0.563 | 0.016 | 0.794 | 0.492 | 0.029 | 0.033 |
| Noncirrhotic HBV-ACLF | 60.4% (116/192) | 67.0% (120/179) | 63.6% (236/371) | 45.3% (87/192) | 54.2% (97/179) | 49.6% (184/371) |
| Cirrhotic HBV-ACLF | 58.5% (69/118) | 64.9% (85/131) | 61.8% (154/249) | 41.5% (49/118) | 50.4% (66/131) | 46.2% (115/249) |
| p value | 0.735 | 0.692 | 0.656 | 0.514 | 0.507 | 0.405 |